IC
DYN icon

Ikarian Capital’s Dyne Therapeutics DYN Stock Holding History

Ikarian Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-113,837
Closed -$1.44M – 196
2025
Q3 		$1.44M Sell
113,837
-250,000
-69% -$2.85M 0.15% 109
2025
Q2 		$3.46M Buy
363,837
+5,000
+1% +$55K 0.67% 47
2025
Q1 		$3.75M Buy
+358,837
New +$5.13M 0.46% 45
2024
Q1 		– Sell
-285,900
Closed -$3.8M – 154
2023
Q4 		$3.8M Buy
+285,900
New +$2.79M 0.36% 68

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Ikarian Capital's DYN Position: Q4 2025 in Review

Ikarian Capital sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 113,837 shares — an estimated $1.44M sold.

Ikarian Capital first reported a position in DYN in Q4 2023 and held it in 4 quarters. The position peaked at $3.8M in Q4 2023. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Ikarian Capital reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 113,837 Dyne Therapeutics shares in Q4 2025, an estimated $1.44M.
  • Ikarian Capital first reported a position in Dyne Therapeutics in Q4 2023 and held it in 4 quarters.
  • Ikarian Capital's Dyne Therapeutics position peaked at $3.8M in Q4 2023.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.